ArticleComprehensive psychiatry2014
Validation of a modified version of the PRIME screen for psychosis-risk symptoms in a non-clinical Kenyan youth sample.
Article in Comprehensive psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hallucinations in Children and Adolescents: An Updated Review and Practical Recommendations for Clinicians.Schizophrenia bulletin · 2019Pooled it
- Confirmatory Factor Analysis of the Telugu Version of the PRIME Screen-revised (PS-R), a Tool to Screen Individuals at Clinical High-Risk for Psychosis.Indian journal of psychological medicine · 2024Article
- Identification of Psychosis Risk and Diagnosis of First-Episode Psychosis: Advice for Clinicians.Psychology research and behavior management · 2024Review
- Kenya Psychosis-Risk Outcomes Study (KePROS): Development of an Accelerated Medicine Partnership Schizophrenia-Aligned Project in Africa.Schizophrenia bulletin open · 2024Article
- Perspective on clinical high-risk for psychosis in Africa.Frontiers in psychiatry · 2023Article
- Longitudinal and cross-sectional validation of the WERCAP screen for assessing psychosis risk and conversion.Schizophrenia research · 2022Article
- Neurocognition in Kenyan youth at clinical high risk for psychosis.Schizophrenia research. Cognition · 2021Article
- Validation of the Korean Version of the 15-Item Community Assessment of Psychic Experiences in a College Population.Psychiatry investigation · 2020Article
- Personality Traits as Markers of Psychosis Risk in Kenya: Assessment of Temperament and Character.Schizophrenia bulletin open · 2020Article
- Associations between Race, Discrimination, Community Violence, Traumatic Life Events, and Psychosis-Like Experiences in a Sample of College Students.Journal of clinical medicine · 2019Article
- Identification of patients with recent-onset psychosis in KwaZulu Natal, South Africa: a pilot study with traditional health practitioners and diagnostic instruments.Social psychiatry and psychiatric epidemiology · 2019Article
- Validation of the Korean Version of the Prodromal Questionnaire-Brief Version in Non-Help-Seeking Individuals.Psychiatry investigation · 2019Article
- A comparative study of psychotic and affective symptoms in Rwandan and Kenyan students.Epidemiology and psychiatric sciences · 2018Article
- Validation of the Korean version of the 16-Item Prodromal Questionnaire in a Non-Help-Seeking College Population.Psychiatry investigation · 2018Article
- Informed consent in the psychosis prodrome: ethical, procedural and cultural considerations.Philosophy, ethics, and humanities in medicine : PEHM · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe PRIME screen is a self-administered questionnaire designed to quickly assess individuals at risk for developing a psychotic disorder. It is shorter in both length and administration time compared to the Structured Interview for Psychosis-Risk Syndromes (SIPS)-a standard instrument for psychosis prodromal risk assessment. Validation of the PRIME against the SIPS has not been reported in large non-clinical populations.
methodsA culturally modified version of the PRIME screen (mPRIME) was administered to Kenyan youth between the ages of 14 and 29. 182 completed both the SIPS and mPRIME. Validation measures (sensitivity, specificity, positive predictive value, negative predictive value) were calculated and the study sample was then broken down into true positives, false positives, and false negatives for comparison on different quantitative measures.
resultsUsing previously suggested thresholds for a positive screen, the mPRIME had a sensitivity of 40% and a specificity of 64.8% for our entire sample. Positive predictive value (PPV) and negative predictive value (NPV) were 12.3% and 89.7%, respectively. Breaking the sample down by questionnaire outcome showed that true-positive individuals scored higher on average rate and intensity of endorsement of mPRIME items compared to false-positive and false-negatives, while false-negatives on average registered disagreement on all mPRIME questionnaire items.
conclusionsThe mPRIME does not appear to be an effective screener of at-risk individuals for psychosis in our non-clinical sample. Further validation efforts in other general populations are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.